Search results
Institute Physician, Dana-Farber Cancer Institute. . Biography. . Jennifer R. Brown, MD, PhD is the Director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute and a Professor of Medicine at Harvard Medical School in Boston, Massachusetts. Dr.
- Jennifer R. Brown, MD, PhD - Dana-Farber
Jennifer R. Brown, MD, PhD is the Director of the CLL Center...
- Jennifer Brown, MD, PhD, Discusses ALPINE Trial - Dana-Farber
Jennifer Brown, MD, PhD, Dana-Farber, presented updated...
- Brown Lab - CLL Center Biorepository and Translational ...
Jennifer R. Brown, MD, PhD - Dana-Farber Cancer Institute -...
- Jennifer R. Brown, MD, PhD - Dana-Farber
Jennifer R. Brown, MD, PhD. Jennifer R. Brown, MD, PhD is the Director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute and the Worthington and Margaret Collette Professor of Medicine in the Field of Hematologic Oncology at Harvard Medical School in Boston, Massachusetts. Dr.
Jennifer R. Brown, MD, PhD is the Director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute and the Worthington and Margaret Collette Professor of Medicine in the Field of Hematologic Oncology at Harvard Medical School in Boston, Massachusetts. Dr. Brown completed a B.S. and M.S. simultaneously in ...
Jennifer Brown, MD, PhD, Dana-Farber, presented updated results of the Phase 3 randomized ALPINE trial at #ASH23. The updated analysis shows in CLL/SLL treat...
- 2 min
- 107
- Dana-Farber Cancer Institute
Dec 20, 2023 · Jennifer Brown, MD, PhD, Dana-Farber, presented updated results of the Phase 3 randomized ALPINE trial at ASH23. The updated analysis shows in CLL/SLL treatment, zanubrutinib maintains superior progression-free survival over ibrutinib. Sign up today!
Jennifer R. Brown, MD, PhD - Dana-Farber Cancer Institute - CLL Center Biorepository and Transnational Laboratory
Dec 14, 2022 · Dana-Farber's Jennifer Brown, MD, PhD, says the phase 3 ALPINE randomized trial shows the drug zanubrutinib is superior to ibrutinib in relapsed/refractory c...
